Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to -$65.4 billion.

  • Astrazeneca's Total Liabilities fell 346.87% to -$65.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$65.4 billion, marking a year-over-year decrease of 346.87%. This contributed to the annual value of -$65.4 billion for FY2025, which is 346.87% down from last year.
  • Latest data reveals that Astrazeneca reported Total Liabilities of -$65.4 billion as of Q4 2025, which was down 346.87% from -$68.5 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Total Liabilities registered a high of $66.1 billion during Q4 2021, and its lowest value of -$68.5 billion during Q3 2025.
  • Its 5-year average for Total Liabilities is -$43.7 billion, with a median of -$62.0 billion in 2023.
  • As far as peak fluctuations go, Astrazeneca's Total Liabilities skyrocketed by 26860.6% in 2021, and later tumbled by 20195.47% in 2024.
  • Quarter analysis of 5 years shows Astrazeneca's Total Liabilities stood at $66.1 billion in 2021, then decreased by 10.07% to $59.4 billion in 2022, then grew by 4.25% to $62.0 billion in 2023, then tumbled by 201.95% to -$63.2 billion in 2024, then decreased by 3.47% to -$65.4 billion in 2025.
  • Its last three reported values are -$65.4 billion in Q4 2025, -$68.5 billion for Q3 2025, and -$67.6 billion during Q2 2025.